Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 3/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220875 | 0.89 | SYK (0.39) | FPR2PDCD1LG2CD274SYKNOS1 | |
| SCHEMBL221745 | 0.80 | FPR2 (0.39) | FPR2MAOBS1PR1NOS3NOS1 | |
| SCHEMBL419969 | 0.79 | NOS3 (0.39) | PDCD1LG2CD274NOS3NOS1NOS2 | |
| SCHEMBL5833770 | 0.77 | NOS3 (0.51) | PDCD1LG2CD274NOS3NOS1NOS2 | |
| SCHEMBL252495 | 0.76 | PDCD1LG2 (0.38) | PDCD1LG2CD274NOS3NOS1NOS2 | |
| SCHEMBL5833737 | 0.74 | NOS1 (0.53) | PDCD1LG2CD274NOS3NOS1NOS2 | |
| SCHEMBL5833043 | 0.74 | NOS3 (0.53) | PDCD1LG2CD274NOS3NOS1NOS2 | |
| SCHEMBL5341095 | 0.73 | PDCD1LG2 (0.38) | PDCD1LG2CD274 | |
| SCHEMBL6582579 | 0.73 | PDCD1LG2 (0.41) | PDCD1LG2CD274NOS3NOS1NOS2 | |
| SCHEMBL220876 | 0.71 | CHEK1 (0.45) | FPR2SYKNOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| WO-2018033639-A1 | LACTONE INTERMEDIATES OF NICOTINAMIDE RIBOSIDE AND NICOTINATE RIBOSIDE | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-02-22 | — | — | WO | disclosed |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-3152220-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-12 | — | — | EP | disclosed |
| EP-3149016-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2006078941-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS OF USE THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006076681-A2 | NOVEL COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE AND BLOOD COAGULATION DISORDERS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-0958282-B1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PROD INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | PFIZER INC. | 2001-07-12 | — | — | US | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NNT, CS, ME2 | FPR2 1472/4885PDE4D 2685/4885CTSS 1731/4885 |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | NNT, HADHB, NAMPT | FPR2 3861/4885PDE4D 826/4885CTSS 750/4885 |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | FPR2 2836/4885PDE4D 725/4885CTSS 359/4885 |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | NOS1, PTGS1, NOS2 | FPR2 72/4885PDE4D 2113/4885CTSS 3494/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | FPR2 3836/4885PDE4D 960/4885CTSS 2618/4885 |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | NNT, HADHB, NAMPT | FPR2 3861/4885PDE4D 826/4885CTSS 750/4885 |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | NNT, CS, ME2 | FPR2 1472/4885PDE4D 2685/4885CTSS 1731/4885 |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | GRIN2C, GRIN2A, CNR2 | FPR2 1248/4885PDE4D 2264/4885CTSS 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.